THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...
As Amgen strives to become the industry’s top player in cardiometabolic risk reduction by the start of the next decade, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results